Cargando…

Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome

INTRODUCTION: Virtually all individuals with Down syndrome (DS) will develop Alzheimer's disease (AD) pathology by age 40. Cerebrospinal fluid (CSF) biomarkers have characterized AD pathology in cohorts of late‐onset AD (LOAD) and autosomal‐dominant AD (ADAD). Few studies have evaluated such bi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henson, Rachel L., Doran, Eric, Christian, Bradley T., Handen, Benjamin L., Klunk, William E., Lai, Florence, Lee, Joseph H., Rosas, H. Diana, Schupf, Nicole, Zaman, Shahid H., Lott, Ira T., Fagan, Anne M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Diagnostic Assessment & Prognosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346867/ https://www.ncbi.nlm.nih.gov/pubmed/32671183 http://dx.doi.org/10.1002/dad2.12057

Ejemplares similares

Metabolic correlates of prevalent mild cognitive impairment and Alzheimer's disease in adults with Down syndrome
por: Mapstone, Mark, et al.
Publicado: (2020)

Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen
por: Zammit, Matthew D., et al.
Publicado: (2021)

Periodontal disease's contribution to Alzheimer's disease progression in Down syndrome
por: Kamer, Angela R., et al.
Publicado: (2016)

Detection of presymptomatic Alzheimer's disease through breath biomarkers
por: Emam, Shadi, et al.
Publicado: (2020)

Developmental lead exposure and lifespan alterations in epigenetic regulators and their correspondence to biomarkers of Alzheimer's disease
por: Eid, Aseel, et al.
Publicado: (2016)

Alzheimer's disease severity, objectively determined and measured
por: Gross, Alden L., et al.
Publicado: (2016)

Insulin resistance is related to cognitive decline but not change in CSF biomarkers of Alzheimer's disease in non‐demented adults
por: Ennis, Gilda E., et al.
Publicado: (2021)

Function and clinical meaningfulness of treatments for mild Alzheimer's disease
por: Siemers, Eric, et al.
Publicado: (2016)

Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease
por: Law, Lena L., et al.
Publicado: (2018)

Diagnosed prevalence of Alzheimer's disease and related dementias in Medicare Advantage plans
por: Jutkowitz, Eric, et al.
Publicado: (2020)

The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions
por: Johnson, Sterling C., et al.
Publicado: (2017)

Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a population-based sample
por: Jung, Youngsin, et al.
Publicado: (2017)

What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals? A systematic review
por: Tochel, Claire, et al.
Publicado: (2019)

Prognostic value of ATN Alzheimer biomarkers: 60‐month follow‐up results from the Argentine Alzheimer's Disease Neuroimaging Initiative
por: Allegri, Ricardo F., et al.
Publicado: (2020)

Meeting physical activity recommendations may be protective against temporal lobe atrophy in older adults at risk for Alzheimer's disease
por: Dougherty, Ryan J., et al.
Publicado: (2016)

Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure
por: Lingler, Jennifer H., et al.
Publicado: (2018)

Revolutionizing Alzheimer's disease and clinical trials through biomarkers
por: Mattsson, Niklas, et al.
Publicado: (2015)

Is diabetes associated with increased pathological burden in Alzheimer's disease?
por: Sadrolashrafi, Kaviyon, et al.
Publicado: (2021)

Dual sensory impairment in older adults and risk of dementia from the GEM Study
por: Hwang, Phillip H., et al.
Publicado: (2020)

Challenges associated with biomarker-based classification systems for Alzheimer's disease
por: Illán-Gala, Ignacio, et al.
Publicado: (2018)

Development and validation of a salivary tau biomarker in Alzheimer's disease
por: Pekeles, Heather, et al.
Publicado: (2018)

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design
por: de Wilde, Arno, et al.
Publicado: (2017)

Assessing quality of life in Alzheimer's disease: Implications for clinical trials
por: Kahle-Wrobleski, Kristin, et al.
Publicado: (2016)

Multimodal prediction of conversion to Alzheimer's disease based on incomplete biomarkers
por: Ritter, Kerstin, et al.
Publicado: (2015)

The Consortium for the early identification of Alzheimer's disease–Quebec (CIMA-Q)
por: Belleville, Sylvie, et al.
Publicado: (2019)

Theoretical frameworks and approaches used within the Reserve, Resilience and Protective Factors professional interest area of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment
por: Bartrés‐Faz, David, et al.
Publicado: (2020)

Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease
por: Dauwan, Meenakshi, et al.
Publicado: (2016)

Relationship between frailty and Alzheimer's disease biomarkers: A scoping review
por: Wallace, Lindsay, et al.
Publicado: (2018)

Copper and zinc isotopic excursions in the human brain affected by Alzheimer's disease
por: Moynier, Frédéric, et al.
Publicado: (2020)

Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study
por: Wang, Hui‐Fu, et al.
Publicado: (2020)

Women's higher brain metabolic rate compensates for early Alzheimer's pathology
por: Sundermann, Erin E., et al.
Publicado: (2020)

Characterizing heterogeneity in the progression of Alzheimer's disease using longitudinal clinical and neuroimaging biomarkers
por: Goyal, Devendra, et al.
Publicado: (2018)

Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin
por: Carro, Eva, et al.
Publicado: (2017)

Pilot study of an Alzheimer's disease risk assessment program in a primary care setting
por: Korthauer, Laura E., et al.
Publicado: (2021)

Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for Alzheimer's disease
por: Bartolome, Fernando, et al.
Publicado: (2021)

Pseudodementia, pseudo‐pseudodementia, and pseudodepression
por: Brodaty, Henry, et al.
Publicado: (2020)

Tauopathy in basal ganglia involvement is exacerbated in a subset of patients with Alzheimer's disease: The Hisayama study
por: Hamasaki, Hideomi, et al.
Publicado: (2019)

Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative
por: Li, Dan, et al.
Publicado: (2018)

Prediction of poor clinical outcome in vascular cognitive impairment: TRACE‐VCI study
por: Boomsma, Jooske M.F., et al.
Publicado: (2020)

Learning to classify neural activity from a mouse model of Alzheimer's disease amyloidosis versus controls
por: Beker, Shlomit, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dqco98bmcafur733ilef8pkfu0